INTEGRATION OF BIOSIMILAR THERAPIES IN ONCOLOGY AND HEMATOLOGY: REGULATORY, CLINICAL, AND PRACTICAL PERSPECTIVES
Fuente:
Zenodo
Enregistré dans:
| Auteur principal: | |
|---|---|
| Format: | Recurso digital |
| Langue: | anglais |
| Publié: |
Zenodo
2025
|
| Sujets: | |
| Accès en ligne: | |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
| _version_ | 1866901257222881280 |
|---|---|
| author | Schneider, Johannes Lukas |
| author_facet | Schneider, Johannes Lukas |
| contents | <p>The regulation of biosimilars is a process that is still developing. In Europe, guidance regarding the approval and use of biosimilars has evolved with the products under consideration. It is now more than 3 years since the first biosimilar agents in oncology support, erythropoiesis-stimulating agents, were approved in the EU. More recently, biosimilar granulocyte colony-stimulating factors have received marketing approval in Europe. This review considers general issues surrounding the introduction of biosimilars and highlights current specific issues pertinent to their use in clinical practice in oncology. Information on marketing approval, extrapolation, labelling, substitution, immunogenicity and traceability of each biosimilar product is important, especially in oncology where patients are treated in repeated therapy courses, often with complicated protocols, and where biosimilars are not used as a unique therapy for replacement of e.g. growth hormone or insulin. While future developments in the regulation of biosimilars will need to address multiple issues, in the interim physicians should remain aware of the inherent differences between biosimilar and innovator products.</p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_17404404 |
| institution | Zenodo |
| language | eng |
| publishDate | 2025 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | INTEGRATION OF BIOSIMILAR THERAPIES IN ONCOLOGY AND HEMATOLOGY: REGULATORY, CLINICAL, AND PRACTICAL PERSPECTIVES Schneider, Johannes Lukas Biosimilars; granulocyte colony-stimulating factor; biologics; substitution; traceability; extrapolation; international non-proprietary names <p>The regulation of biosimilars is a process that is still developing. In Europe, guidance regarding the approval and use of biosimilars has evolved with the products under consideration. It is now more than 3 years since the first biosimilar agents in oncology support, erythropoiesis-stimulating agents, were approved in the EU. More recently, biosimilar granulocyte colony-stimulating factors have received marketing approval in Europe. This review considers general issues surrounding the introduction of biosimilars and highlights current specific issues pertinent to their use in clinical practice in oncology. Information on marketing approval, extrapolation, labelling, substitution, immunogenicity and traceability of each biosimilar product is important, especially in oncology where patients are treated in repeated therapy courses, often with complicated protocols, and where biosimilars are not used as a unique therapy for replacement of e.g. growth hormone or insulin. While future developments in the regulation of biosimilars will need to address multiple issues, in the interim physicians should remain aware of the inherent differences between biosimilar and innovator products.</p> |
| title | INTEGRATION OF BIOSIMILAR THERAPIES IN ONCOLOGY AND HEMATOLOGY: REGULATORY, CLINICAL, AND PRACTICAL PERSPECTIVES |
| topic | Biosimilars; granulocyte colony-stimulating factor; biologics; substitution; traceability; extrapolation; international non-proprietary names |
| url | https://doi.org/10.5281/zenodo.17404404 |